Search research articles
Contact Us
Filters
Showing results (61-70 of 66) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 66 results.
JAMA
|
June 26, 2019
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial
Joo-Yong Hahn, Young Bin Song, Ju-Hyeon Oh, et al.
JAMA Cardiology
|
September 28, 2022
Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial
Ki Hong Choi, Yong Hwan Park, Young Bin Song, et al.
Heart (British Cardiac Society)
|
March 24, 2021
P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor
Juwon Kim, Woo Jin Jang, Wang Soo Lee, et al.
Journal of the American Heart Association
|
December 21, 2020
Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial
Kyeong Ho Yun, Seung-Yul Lee, Byung Ryul Cho, et al.
American Heart Journal
|
February 8, 2023
Immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: results from a prematurely discontinued randomized multicenter trial
Soohyung Park, Seung-Woon Rha, Byoung Geol Choi, et al.
Cardiology Journal
|
September 15, 2021
P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial
Ji Woong Roh, Joo-Yong Hahn, Ju-Hyeon Oh, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 66) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 66 results.
JAMA
|
June 26, 2019
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial
Joo-Yong Hahn, Young Bin Song, Ju-Hyeon Oh, et al.
JAMA Cardiology
|
September 28, 2022
Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial
Ki Hong Choi, Yong Hwan Park, Young Bin Song, et al.
Heart (British Cardiac Society)
|
March 24, 2021
P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor
Juwon Kim, Woo Jin Jang, Wang Soo Lee, et al.
Journal of the American Heart Association
|
December 21, 2020
Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial
Kyeong Ho Yun, Seung-Yul Lee, Byung Ryul Cho, et al.
American Heart Journal
|
February 8, 2023
Immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: results from a prematurely discontinued randomized multicenter trial
Soohyung Park, Seung-Woon Rha, Byoung Geol Choi, et al.
Cardiology Journal
|
September 15, 2021
P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial
Ji Woong Roh, Joo-Yong Hahn, Ju-Hyeon Oh, et al.
Page
of 7